CJC-1295 no DAC / Ipamorelin research: quick summary
This listing is a two-component research pairing: 5 mg of modified GRF (1-29), sold as CJC-1295 no DAC, and 5 mg of ipamorelin, a synthetic pentapeptide ghrelin receptor agonist. The two are studied at different receptors. Neither is an authorized medicine in Canada, both are for laboratory research only, neither is for human or veterinary use, and no dosing or protocol information is provided.
CJC-1295 no DAC / Ipamorelin Canada: CJC-1295 no DAC 5mg / Ipamorelin 5mg Research Product
The pairing is stocked as two lyophilized research chemicals for qualified purchasers in Canada, described by both materials, their lot paperwork and dispatch.
Visitors arrive on buy CJC-1295 Ipamorelin Canada, CJC-1295 Ipamorelin peptide Canada and mod GRF 1-29 Ipamorelin Canada. Those are search strings, not purposes. Anyone with a personal-health motive should speak with a clinician.
Red Leaf Research Labs supplies both components as research chemicals. We do not sell them for administration to humans or animals, give no dosing or combination instructions, and make no claim about what either does.
CJC-1295 no DAC 5mg / Ipamorelin 5mg Research Format and Options
| Attribute | Detail |
|---|
| Research format | 5 mg modified GRF (1-29) and 5 mg ipamorelin, lyophilized |
| Physical state | Two dried cakes, each in a sealed glass vial |
| Analytical documentation | One independent report per component lot, methods named |
| Fulfilment | Dispatch inside Canada to research addresses |
| Intended use | Laboratory research only; not for human or veterinary use |
A blend raises a documentation requirement a single vial does not: coverage must exist for each constituent, since a report on one peptide says nothing about the other.
CJC-1295 no DAC / Ipamorelin Research Specifications
Component 1: modified GRF (1-29)
- Compound name: Modified GRF (1-29)
- Alternative name(s) and research shorthand: CJC-1295 without DAC, mod GRF 1-29
- Peptide/compound class: Synthetic GHRH analogue, 29 residues
- Receptor or pathway interest: GHRH receptor (GHRHR), anterior pituitary
- Structural origin: GRF(1-29) amide, D-Ala2, Gln8, Ala15, Leu27
- CAS: 863288-34-0
- Molecular formula: C152H252N44O42
- Molecular weight: approximately 3367.9 g/mol
Component 2: ipamorelin
- Compound name: Ipamorelin
- Alternative name(s) and research shorthand: NNC 26-0161, Ipa
- Peptide/compound class: Synthetic pentapeptide secretagogue
- Receptor or pathway interest: GHS-R1a, the ghrelin receptor
- Structural origin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- CAS: 170851-70-4
- Molecular formula: C38H49N9O5
- Molecular weight: approximately 711.9 g/mol
Both components: quantity 5 mg, physical format lyophilized solid, intended use laboratory research only, fulfilment domestic Canadian dispatch.
What Is CJC-1295 no DAC / Ipamorelin?
Modified GRF (1-29) is the first twenty-nine residues of human growth hormone releasing hormone, C-terminally amidated, with four substitutions: D-alanine at 2, glutamine at 8, alanine at 15, leucine at 27. Ipamorelin is unrelated: a five-residue peptide of aminoisobutyric acid, D-2-naphthylalanine and D-phenylalanine, residues no ribosome incorporates.
The confusion here is the trade name on the first component. CJC-1295 no DAC is not CJC-1295 with DAC, CAS 446262-90-4, which carries an extra maleimidopropionyl lysine and weighs about 3647.2. Ipamorelin is grouped with GHRP-2 and GHRP-6, separate sequences with their own CAS numbers.
CJC-1295 no DAC / Ipamorelin and Growth Hormone Axis Receptor Research
The components are studied at two receptors. Work on GRF(1-29) analogues concerns the GHRH receptor of pituitary somatotrophs, a class B receptor described by cyclic AMP generation. Work on ipamorelin concerns GHS-R1a, the ghrelin receptor. Raun and colleagues characterised it in rat pituitary cells, anaesthetised rats and conscious swine in the European Journal of Endocrinology in 1998, reporting growth hormone release without the corticotropin and cortisol changes seen with GHRP-6 and GHRP-2.
Those are measurements by others in cells and animal models. Receptor activity in a model does not establish an effect in a person, and no statement is made about the two together.
Why Buy CJC-1295 no DAC 5mg / Ipamorelin 5mg in Canada from a Domestic Research Supplier?
A pairing carries two consignment histories, not one. A domestic route shortens both at once.
It also concentrates responsibility: two lots, two certificates, and one component whose trade name is shared with another molecule.
These are supply-chain points. Neither powder is improved, and both certificates still need reading.
How This CJC-1295 no DAC / Ipamorelin Canada Page Improves on Typical Competitor Listings
Blend listings are where template copy fails most. This page differs in five ways.
- Both constituents are specified separately, with their own CAS, formula and mass.
- The analytical basis is stated per component: a report tied to each lot and its methods.
- No effect or safety property is asserted for either component.
- The regulatory position is explicit: two research chemicals, neither authorized.
- Structural relationships are named, separating mod GRF (1-29) from the DAC conjugate.
How to Evaluate a CJC-1295 no DAC / Ipamorelin Certificate of Analysis
Two documents, not one. The components differ by roughly a factor of five in mass, and no certificate covers both.
- Compound identity: modified GRF (1-29) at CAS 863288-34-0, ipamorelin at CAS 170851-70-4.
- Lot reference: each certificate carries the lot of its own vial.
- Analysis date: a testing date on each; the vials were not necessarily made together.
- Test methods: methods per component, conditions for a 29-mer not suiting a pentapeptide.
- Measured quantity: 5 mg accounted for on each document, not 10 mg on one.
- Purity result: a separate figure per component, each with its method.
- Laboratory verification: the laboratory on each certificate, and its link to the seller.
Mass identifies each unambiguously, but confirming the GRF component lacks the drug affinity complex means reading 279 daltons off the number.
CJC-1295 no DAC 5mg / Ipamorelin 5mg Lyophilized Research Format
Both vials are freeze-dried: frozen, then dried under vacuum as the ice sublimes.
The two cakes are not comparable. Five milligrams of a 3368 dalton peptide and five of a 712 dalton pentapeptide hold very different molecule counts, so bulk differs and each vial needs its own record. Reconstitution is flagged as requiring advanced technique, so each follows a procedure the laboratory has validated.
Working out concentration for this vial? Our peptide reconstitution calculator converts vial size and bacteriostatic water volume into mg per mL and U-100 syringe units.
How to Buy CJC-1295 no DAC / Ipamorelin in Canada for Qualified Research
- Confirm eligibility. Check both components fall inside your organization’s permissions.
- Review documentation. Read both lot reports; a missing one means a missing component.
- Select quantity. Decide how many pairings the written plan requires.
- Check shipping route. Confirm route and transit window against receiving hours.
- Record receipt. Log two lot numbers, the date and each vial’s condition.
Purchasing and record-keeping only; no dosing or combination advice follows.
CJC-1295 no DAC / Ipamorelin Availability in Canada: Research vs. Consumer Searches
Pairings of a GHRH analogue with a secretagogue are widely discussed outside laboratory contexts, and much of the search traffic here comes from there. None of it appears on this page.
Neither component is an authorized medicine in Canada. Ipamorelin was investigated as NNC 26-0161 and did not become a marketed product; modified GRF (1-29) has no approval anywhere. Neither has been assessed by Health Canada.
A personal-health interest in either belongs with a licensed clinician, not this listing.
CJC-1295 no DAC 5mg / Ipamorelin 5mg Canada Procurement Checklist
| Check | What to confirm |
|---|
| Purpose | Laboratory research in an organization eligible for both items |
| Identity | CAS 863288-34-0 and 170851-70-4, each on its own label and report |
| Distinctness | A GRF component near 3368 daltons, so not the conjugated version |
| Quantity | 5 mg accounted for in each vial separately |
| Documentation | Two lot reports, methods appropriate to each molecule |
| Verification | Whether outside analysis covers one component or both |
| Handling | Separate handling records and a validated procedure for each |
Explore CJC-1295 no DAC / Ipamorelin Research Information
Background reading: third-party testing, how peptides work, and identifying irresponsible suppliers in Canada.
CJC-1295 no DAC / Ipamorelin research FAQ
Does Red Leaf Research Labs provide dosing information?
No. No dosing, reconstitution volume, concentration, route, protocol or combination guidance is provided for any product.
Why does a blend listing need two certificates of analysis?
Because a report characterises one material by one method. A document naming ipamorelin says nothing about the GRF component.
Are the two components the same class of compound?
No. Modified GRF (1-29) is a GHRH analogue studied at GHRHR; ipamorelin is described at GHS-R1a.
Is the GRF component the same as CJC-1295 with DAC?
No. This is CAS 863288-34-0; the DAC conjugate is CAS 446262-90-4.
Can Red Leaf Research Labs advise on using the two together?
No. Combination, sequencing and study design are for the purchasing laboratory.
Research use only. Modified GRF (1-29) 5 mg and ipamorelin 5 mg are supplied strictly for laboratory research. Neither is an authorized medicine in Canada, neither is for human or veterinary use, and no dosing or protocol information accompanies them. Personal-health questions belong with a licensed clinician.
Independent third-party testing
Janoshik Lab Reports
Review available analytical reports associated with this product.
ANALYTICAL
REPORT
Independent analysis
CJC-1295 no DAC (mod GRF 1-29)
- Purity
- 99.754%
- Tested quantity
- 9.78 mg
- Report date
- March 25, 2026
- Task ID
- #123260
ANALYTICAL
REPORT
Independent analysis
Ipamorelin
- Purity
- 99.848%
- Tested quantity
- 10.33 mg
- Report date
- March 25, 2026
- Task ID
- #123269
A certificate describes the submitted sample shown in that report. It does not establish clinical safety, efficacy, or suitability for human or veterinary use.
Owned and operated by a cf veteran 
